|Trust manager||Neil Woodford|
|Trust name||Woodford Patient Capital Trust plc|
|Investment manager||Woodford Investment Management Ltd|
|Investment objective||The Company's investment objective is to achieve long-term capital growth through investing in a diversified portfolio with a focus on UK companies, both quoted and unquoted. As these companies evolve, the geographical profile of the portfolio may also change to become more global in nature for reasons such as an overseas listing or as the result of changes to the capital value of a non-UK company.
The Company will aim to deliver a return in excess of 10 per cent per annum over the longer term1.
View investment policy
|Independent board directors||Susan Searle (Chair)
Dame Pamela Louise Makin
|Total assets (GBP)||£808.4m|
Latest trust update
In October, we continued to see meaningful operational progress across a number of holdings, with encouraging news coming from the likes of Idex, ReNeuron and Mereo BioPharma…
Source: Financial Express, Woodford
|1 month||3 months||Year-to-date||1 year||Since launch
|Net asset value||-3.40||-6.92||3.74||6.18||-2.73|
|Ordinary share price||-6.24||-14.20||-1.76||0.85||-10.60|
|Net asset value||-||-||-||-1.14||5.02|
|Ordinary share price||-||-||-||-11.14||2.20|
Past performance cannot be relied upon as a guide to future performance.
Source: Financial Express on a total return basis, with net income reinvested.
|Oxford Nanopore (unquoted)||Health Care||8.94|
|Immunocore A (unquoted)||Health Care||7.23|
|Benevolent AI (unquoted)||Technology||6.04|
|Autolus (unquoted)||Health Care||5.53|
|Mereo Biopharma||Health Care||4.50|
|Proton Partners International (unquoted)||Health Care||4.27|
|Theravance Biopharma||Health Care||3.84|
|Oxford Sciences Innovation (unquoted)||Financials||3.41|
|Total (of top 10)||67.40|
|Cash and near cash||-17.57|
Prices and fees
|Market share price||89.40p|
|Net asset value (Ex Income)||97.27p|
|Net asset value (Cum Income)||97.27p|
|Annual management fee||None|
|Performance fee||15% of any excess returns over a 10% cumulative hurdle rate per annum, subject to a high watermark|
|Ongoing annual expenses||0.18%|
- This is a target only, not a profit forecast, and there can be no assurance that it will be met.